Rogers

Another anti cannabis propaganda piece ran in the New York Times today (hmm wonder why), written through the lens of a “drug addiction” reporter. That framing matters, because it shapes everything that follows. This is not a neutral assessment of medical cannabis. It is cannabis viewed primarily as a substance of abuse, presented as a general health analysis. The article claims medical cannabis has little evidence of benefit, while also acknowledging that cannabis spent decades classified as Schedule I, legally defined as having no medical value. That classification made large, high-quality clinical trials extremely difficult if not impossible. When research is restricted by law, the absence of definitive evidence should not be treated as proof that something does not work. The article undermines its own thesis by acknowledging FDA approved cannabinoid medications. Epidiolex, which is derived from the cannabis plant, along with synthetic cannabinoids like Marinol, Syndros, and Cesamet, are described as effective for seizures, chemotherapy related nausea, and appetite loss. These drugs were able to be studied and approved because they could move through conventional regulatory pathways, allowing for standardization and large clinical trials. The same pattern appears with pain, anxiety, and sleep, where evidence is called weak while THC and CBD signals are still acknowledged. Risk framing is similarly selective. The article emphasizes cannabis use disorder, citing rates of 29% to 34% without distinguishing mild from severe symptoms or offering meaningful comparison. Alcohol, by contrast, is rarely framed this way despite causing about 140,000 deaths per year in the United States. How risks are framed matters. Finally, the article claims dispensary cannabis lacks reliable monitoring and remains at risk for contamination. That is simply inaccurate. State regulated cannabis is one of the most heavily tested and traceable consumer products sold in the United States, with mandatory third party lab testing, batch tracking, and recall systems. The lack of a single national standard is a result of federal prohibition, and has nothing to do with the state regulated industry. Taken together, this article does not show that cannabis lacks medical value. It shows how an addiction first lens and decades of bad policy can turn regulatory constraints into supposed “scientific conclusions.”